Syndax Pharmaceuticals drops on wider quarterly loss

Syndax Pharmaceuticals

03/03/2025 17:08

** Shares of drug developer Syndax Pharmaceuticals SNDX.O fall 5% to $14.86

** Co posts Q4 net loss of $94.2 million, compared to $72.5 million a year ago

** Reports Q4 operating expenses of $96.4 million, compared to $77.91 million a year ago

** Co reports Q4 sales of $7.7 mln for its first commercial product, Revuforj, chemically known as revumenib, to treat a type of blood cancer

** Expects to seek regulatory approval for revumenib to treat a type of cancer that starts in bone marrow in Q2 2025

** SNDX's shares have fallen 35% in the last 12 months

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))